Dr Haad's peptide stack claims, fact-checked
Instagram creator
Quick answer
The video recommends a five-compound injectable protocol including two growth hormone secretagogues (sermorelin and tesamorelin), a dual GIP/GLP-1 agonist (tirzepatide), IV NAD+, and injectable glutathione for a presumably healthy adult male seeking body recomposition and longevity benefits. Tesamorelin holds FDA approval specifically for HIV-associated lipodystrophy, and sermorelin's approved use is pediatric growth hormone deficiency, meaning both are being discussed here well outside their evidence base. Tirzepatide has the strongest clinical data of the group, but its compounded form is not equivalent to FDA-approved Mounjaro or Zepbound.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @haadmd actually say?
The creator reviewed five injectables, naming NAD+, sermorelin, tesamorelin, tirzepatide, and glutathione, and rated the stack "8.5 out of 10. Strong." They dropped tesamorelin from their personal recommendation, saying sermorelin is better for men and tesamorelin better for women. The core pitch: these compounds together address energy, body composition, metabolic health, and antioxidant load in one protocol.
A few naming errors stood out immediately. "Somoralin" and "Tethymoralin" are sermorelin and tesamorelin respectively. "Tresapatid" is tirzepatide, a dual GIP/GLP-1 receptor agonist, not a peptide in the traditional compounding sense. These aren't just pronunciation slip-ups; they matter when patients try to research what they're being recommended.
Does the science back this up?
Partially, depending on which compound and which claim you examine. The evidence quality varies dramatically across the five. Some claims are well-supported in specific populations. Others are extrapolated from narrow clinical contexts into broad wellness promises that the data does not justify.
NAD+ precursor supplementation has shown modest effects on cellular energy metabolism in older adults, though IV NAD+ specifically has limited robust clinical trial data. Sermorelin is FDA-cleared for pediatric growth hormone deficiency, not adult body recomposition. Tesamorelin has one specific FDA-approved indication: HIV-associated lipodystrophy. Tirzepatide (Mounjaro/Zepbound) does have strong cardiovascular and metabolic data, including the SURMOUNT and SURPASS trials. Glutathione as an injectable antioxidant has theoretical appeal but weak direct clinical evidence for the brain fog and gut claims made here.
What did they get wrong (or right)?
They got tirzepatide broadly right. Calling it "much more than a weight loss medication" is defensible. The SURPASS-CVOT data and inflammation biomarker work support meaningful metabolic and cardiovascular benefits beyond weight (Bhatt et al., 2023, NEJM). Credit where it's due.
The sermorelin-for-men, tesamorelin-for-women framing is not supported by the literature. It appears to be clinical intuition or personal preference, not evidence. Tesamorelin's visceral fat reduction data comes almost entirely from HIV-positive patients with lipodystrophy (Falutz et al., 2007, NEJM), not healthy adults seeking body recomposition. Recommending it for general wellness is a significant extrapolation. The claim that sermorelin increases muscle mass and decreases belly fat in healthy adults also lacks strong RCT support. Growth hormone secretagogues have been studied, but effects in eugonadal adults without GH deficiency are modest at best (Svensson et al., 1998, Journal of Clinical Endocrinology and Metabolism). Saying glutathione will help with "toxic free radicals and toxic burden" is vague enough to be nearly unfalsifiable, and the gut health claim specifically has minimal direct injectable evidence.
What should you actually know?
Several of these compounds are only legally available as compounded drugs in the US, and compounded versions are not equivalent to FDA-approved formulations. Tirzepatide compounding has been a moving target with FDA enforcement, and sermorelin's regulatory status as a compounded product has faced scrutiny. None of this is mentioned in the video.
Running five injectables simultaneously also creates a real monitoring problem. There is no published safety data on this specific combination. Growth hormone axis stimulation alongside a GLP-1/GIP agonist alongside NAD+ and glutathione is not a studied protocol. Interactions are not well characterized. A rating of 8.5 out of 10 implies a confidence the available evidence cannot support. Patients watching this should know that an enthusiastic physician review of a friend's stack is not the same as a personalized medical evaluation. These compounds carry real side effect profiles, require lab monitoring, and several have only narrow approved indications that do not include general wellness or anti-aging.
Bottom line on this stack
Two of the five compounds have solid evidence bases in specific contexts. The other three are being used well outside their studied or approved populations. The sex-based sermorelin-versus-tesamorelin split is not evidence-based. The "master antioxidant" framing for glutathione is marketing language, not clinical language. If you're considering any of these, the conversation should start with your own labs, your own health history, and a clinician reviewing you, not a friend's stack.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Dr Haad's peptide stack claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The video recommends a five-compound injectable protocol including two growth hormone secretagogues (sermorelin and tesamorelin), a dual GIP/GLP-1 agonist (tirzepatide), IV NAD+, and injectable glutathione for a presumably healthy adult male seeking body recomposition and longevity benefits.
FormBlends verdict
The video recommends a five-compound injectable protocol including two growth hormone secretagogues (sermorelin and tesamorelin), a dual GIP/GLP-1 agonist (tirzepatide), IV NAD+, and injectable glutathione for a presumably healthy adult male seeking body recomposition and longevity benefits. Tesamorelin holds FDA approval specifically for HIV-associated lipodystrophy, and sermorelin's approved use is pediatric growth hormone deficiency, meaning both are being discussed here well outside their evidence base. Tirzepatide has the strongest clinical data of the group, but its compounded form is not equivalent to FDA-approved Mounjaro or Zepbound.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video recommends a five-compound injectable protocol including two growth hormone secretagogues (sermorelin and tesamorelin), a dual GIP/GLP-1 agonist (tirzepatide), IV NAD+, and injectable glutathione for a presumably healthy adult male seeking body recomposition and longevity benefits. Tesamorelin holds FDA approval specifically for HIV-associated lipodystrophy, and sermorelin's approved use is pediatric growth hormone deficiency, meaning both are being discussed here well outside their evidence base. Tirzepatide has the strongest clinical data of the group, but its compounded form is not equivalent to FDA-approved Mounjaro or Zepbound.
- Tesamorelin's FDA approval is specifically for HIV-associated lipodystrophy; visceral fat reduction data in healthy adults is extrapolated from a narrow patient population (Falutz et al., 2007, NEJM).
- Tirzepatide has the strongest evidence base of the five, with SURPASS and SURMOUNT trials showing metabolic and cardiovascular benefits, but compounded tirzepatide is not equivalent to FDA-approved Mounjaro or Zepbound.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Tesamorelin's FDA approval is specifically for HIV-associated lipodystrophy; visceral fat reduction data in healthy adults is extrapolated from a narrow patient population (Falutz et al., 2007, NEJM).
- Tirzepatide has the strongest evidence base of the five, with SURPASS and SURMOUNT trials showing metabolic and cardiovascular benefits, but compounded tirzepatide is not equivalent to FDA-approved Mounjaro or Zepbound.
- The claim that sermorelin is better for men and tesamorelin better for women has no published clinical basis and appears to reflect personal clinical preference, not evidence.
- No published safety data covers the simultaneous use of all five compounds in this stack, meaning the 8.5/10 rating is not grounded in studied protocol data.
- Sermorelin's approved use is pediatric growth hormone deficiency; its use in healthy adult men for muscle gain and fat loss is off-label with modest supporting evidence at best (Svensson et al., 1998, Journal of Clinical Endocrinology and Metabolism).
- Injectable glutathione's benefits for brain fog, energy, and gut health in healthy adults lack rigorous RCT support despite the compound's sound antioxidant mechanism.
- Several of these compounds exist only as compounded drugs in the US, a regulatory reality the video does not address, and compounded formulations carry different quality and oversight standards than FDA-approved products.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr Haad Mahmood, MD | Anti-Aging & Regenerative Medicine · Instagram creator
5.0K views on this video
My friend showed me this peptide stack to review 💉🔥 What would YOU rate it from 1-10?! 💥 NAD+ — focus, energy, anti-aging 💪 Sermorelin — builds muscle, burns fat, improves recovery + sleep 🔥 Tes
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr Haad Mahmood, MD | Anti-Aging & Regenerative Medicine, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.